Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging?
Gastrin-releasing peptide (GRP) has been shown to be a tumour growth stimulating agent for a number of normal and human cancer cell lines. The tumour growth effect is a direct result of GRP binding to membrane G-protein coupled GRP receptors (GRP-R) on the cell surface. Available data on the role of GRP and GRP-R in human lung, prostate, breast, colorectal and gastric carcinoma are reviewed and it is suggested that radiolabelled agonists are preferable to antagonists for imaging and therapy as they appear to be internalised, yielding a higher target/background ratio. The use of rhenium or indium radiolabels for therapy may provide a new approach to GRP/bombesin expressing tumours.
Division of Nuclear Medicine, University Hospital Ghent, Belgium. Christophe.Vandewiele@rug.ac.be
C
C
Van de Wiele
F
F
Dumont
S
S
van Belle
G
G
Slegers
S H
SH
Peers
R A
RA
Dierckx
D001839:Bombesin; D019886:Gastrin-Releasing Peptide / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D018004:Receptors, Bombesin / Q000378:metabolism*
D019275:Radiopharmaceuticals; D018004:Receptors, Bombesin; D019886:Gastrin-Releasing Peptide; D001839:Bombesin